A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min

Trial Profile

A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone; Thalidomide
  • Indications Myeloma
  • Focus Therapeutic Use
  • Acronyms OPTIMAL
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 12 Jun 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2018.
    • 12 Jun 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 04 Nov 2015 Accrual to Date is 2% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top